HOME >> BIOLOGY >> NEWS
Targeted Genetics presents advances in systemic gene delivery technology

--Intravenous gene delivery demonstrates efficacy in pre-clinical studies of breast cancer and head and neck cancer--

San Francisco, CA -- April 3, 2000 -- Targeted Genetics Corporation (Nasdaq: TGEN) today presented data on the company's synthetic gene delivery platform at the American Association of Cancer Research 91st Annual Meeting being held in San Francisco. Dr. Pervin Anklesaria, Senior Director of Research at Targeted Genetics, presented data indicating that the company's LPD (Lipid Polycation DNA) gene delivery system is capable of delivering genes systemically when delivered intravenously. Intravenous delivery of tgLPD-E1A, the company's second-generation cancer therapeutic, inhibited tumor growth in animal models of two different human tumors. The data were presented in an abstract titled "Systemic and Local Delivery of E1A-Cationic Lipid Complex Chemosensitizes Breast and Ovarian Cancer Cells In Vivo."

Advances in Systemic Gene Delivery Technology
In a study presented today, the LPD delivery system was used to deliver E1A, a proprietary tumor inhibitor gene, systemically to mice transplanted with human head and neck tumors. tgLPD-E1A was administered weekly beginning six days after tumor cells were transplanted into the animals. These cells express basal levels of HER-2/neu. At 13 weeks, 70 percent of the animals treated with tgLPD-E1A were tumor free, compared to only 10 percent of animals receiving either lipid alone or 5FU, and only 50 percent of animals receiving a lipoplex-E1A control.

"We have now demonstrated that intravenous delivery of tgLPD-E1A is able to inhibit tumor growth in animal models of breast and head and neck cancers," said Dr. Anklesaria. "These data show that the LPD gene delivery system may enable the systemic delivery of therapeutic genes, an important step in the evolution of gene delivery technologies. Significantly, tgLPD-E1A was seven-fold more effective at inhib
'"/>

Contact: Page Sargisson
p.sargisson@noonanrusso.com
415-677-4455 x229
Noonan/Russo Communications
2-Apr-2000


Page: 1 2 3 4

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. Targeted therapy for lung cancer patients shows promise in extending lives
3. Targeted immunotherapy eradicates cancer in mice
4. Targeted radiation to liver tumors spares tissue, improves quality of life
5. Targeted Genetics presents data on arthritis gene therapy
6. Targeted genetics presents promising data from cystic fibrosis clinical trial
7. Targeted Genetics presents clinical data on E1A cancer gene therapy
8. Targeted Genetics presents advances in synthetic gene delivery technologies
9. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
10. Fred Hutchinson Cancer Research Center And Targeted Genetics Announces Issuance Of Braod Patent Covering Antigen-Specific T Cell Expansion
11. Marine Snail Toxin Targeted At African Toad Eggs Reveals Novel Impact On The Regulation Of Serotonin

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/4/2019)... DIEGO (PRWEB) , ... June 04, 2019 , ... Lajollacooks4u ... of Fame recipients. The recognition, which honors hospitality excellence, is given only to businesses ... Certificate of Excellence for five consecutive years. , To qualify for the ...
(Date:5/31/2019)... ... May 30, 2019 , ... Researchers from Ambry Genetics ... significant differences in the prevalence of hereditary genetic mutations, also called germline mutations, ... women. Results will be presented at the 2019 American Society of Clinical Oncology ...
(Date:5/26/2019)... MILWAUKEE (PRWEB) , ... May 24, 2019 , ... Zolgensma ... known as AVXS-101, was approved for clinical use in the United States by the ... second virally-delivered gene therapy approved to treat inherited genetic disorders in the United States ...
Breaking Biology News(10 mins):
(Date:5/4/2019)... N.J. (PRWEB) , ... May 03, 2019 , ... ... announces the release of the Diopsys® ffERG/Photopic Negative Response vision test, ... glaucoma. , By 2050, it is estimated that 6.3 million Americans will have ...
(Date:5/2/2019)... ... May 02, 2019 , ... Stay on top of current ... and food industries. Access to all webinars is free, so be sure to register ... field! , Visit http://www.xtalks.com to see our upcoming webinars: , CLINICAL TRIALS ...
(Date:4/25/2019)... ... April 23, 2019 , ... Frank is an albino, deaf Great Dane. His owners ... him due to his health issues. Despite his hearing impairment, he was always an active ... two would play all day, every day. As the two grew, playtime became rougher and ...
(Date:4/16/2019)... ... April 16, 2019 , ... ... their project partner, the U.S. Army Center for Environmental Health Research (USACEHR), with ... Combined In-Licensing/Out-Licensing.” , Blue Sources, a veteran-owned company located at the Frederick Innovative ...
Breaking Biology Technology:
Cached News: